Back to results
US 2024/0287002 A1Published application
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
AssigneeExelixis, Inc.
InventorsDana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy, Linh Nguyen
Life of this patent
Estimating the term…
Abstract
The invention relates to metabolites of cabozantinib (I) as well as uses thereof.
Claims19
An isolated metabolite of cabozantinib or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising:
- or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
A compound which is selected from:
- wherein GA is a glucuronic acid moiety, or a pharmaceutically acceptable salt thereof.
A method for identifying a metabolite of cabozantinib, comprising:
- administering cabozantinib to a mammal;
- detecting or measuring a level or concentration of a metabolite of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in a mammal in tissues or bodily fluids of the mammal;
- wherein the metabolite is selected from the group consisting of:
- wherein GA is a glucuronic acid moiety.
1 more element
Dependencies are inferred from the claim text.